SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
ALEXZA PHARMACEUTICALS
(NQNM:ALXA Last Sale: 5.12 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (ALXA : $5.12)
$170 million Market Cap at September 12, 2013
Biomedics SubIndustry up .00% / Health Industry up .00% Today
1020 East Meadow Circle Research Report Earnings Snapshot - Last 11/05/18
Palo Alto, CA 94303 Fact Sheet
Phone: (650) 687-3900 Financial Statements
Peer Comparison
Annual Reports

Thomas B. King, Pres./CEO
Focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. Our technology, the Staccato system, vaporizes unformulated drug compound to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. IPO at $8 March 7, 2006. Raised $44 million, selling 5.5 million shares, 24% of the outstanding. Lead Manager: Piper Jaffray.
Historical Charts    Technical Analysis
No Historical Data available for ALXA

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common ALXA $5.12 $ 0 $5.095 $5.19 196,229 $3.78 $6.6499 33,204
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $170,004

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex